CDT EQUITY INC. Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect
CDT EQUITY INC. (CDT) reported Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect of -$764.00 thousand for the 6-month period ending 2026-06-30, per its S-1 filed 2026-09-08.
Financial Statements › Cash Flow › Change in Cash
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect · last filed 2026-09-08
- CDT EQUITY INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2026-03-31 was -$1.41M, a 188.27% decline year-over-year.
- CDT EQUITY INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2025-03-31 was $1.59M.
- CDT EQUITY INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2024-03-31 was -$2.36M, a 33771.43% decline year-over-year.
- CDT EQUITY INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2023-03-31 was $7.00K.
- CDT EQUITY INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2023 was $3.93M.
- CDT EQUITY INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2022 was -$1.00K.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 3 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 6 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 9 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$764.00K S-1 · filed 2026-09-08 | |||
| 2026-03-31 | -$1.41M 10-Q · filed 2026-07-15 | |||
| 2025-12-31 | $1.06M S-1 · filed 2026-09-08 | |||
| 2025-09-30 | $3.36M 10-Q · filed 2025-11-13 | |||
| 2025-06-30 | $2.77M S-1 · filed 2026-09-08 | |||
| 2025-03-31 | $1.59M 10-Q · filed 2026-07-15 | |||
| 2024-12-31 | -$3.66M S-1 · filed 2026-09-08 | |||
| 2024-09-30 | -$4.14M 10-Q · filed 2025-11-13 | |||
| 2024-06-30 | -$3.98M 10-Q · filed 2025-08-14 | |||
| 2024-03-31 | -$2.36M 10-Q/A · filed 2025-08-14 | |||
| 2023-12-31 | $3.93M 10-K · filed 2025-03-28 | |||
| 2023-09-30 | $8.65M 10-Q · filed 2024-11-14 | |||
| 2023-06-30 | -$6.00K 10-Q/A · filed 2024-11-14 | |||
| 2023-03-31 | $7.00K 10-Q/A · filed 2024-11-14 | |||
| 2022-12-31 | -$1.00K 10-K · filed 2024-04-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aditxt, Inc. (ADTX) | United States | $0.000B | |
| Rafael Holdings, Inc. (RFL) | United States | $0.000B | -0.00 |
| Protagenic Therapeutics, Inc.\new (PTIX) | United States | $0.001B | |
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B |